Prognostic factors for post-recurrence survival among patients with locally advanced cervical cancer who underwent definitive concurrent chemoradiation

Pitchaya Thongkhao, Narumon Janmunee, Aimwarin Tangkananan
Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand

ABSTRACT

Background: The prognostic factors affecting post-recurrence survival (PRS) in patients with locally advanced cervical cancer (LACC) who receive concurrent chemoradiation (CCRT) are not well established. This study aimed to assess the prognostic factors for PRS in patients with recurrent LACC who underwent CCRT as the primary treatment.

Materials and methods: We retrospectively reviewed the medical records of patients with a first recurrence of cervical cancer (stage IB2–IVA), who were initially treated with CCRT and completed the planned radiotherapy from 2002 to 2018. Multivariate analysis of independent factors for PRS was performed with the Cox proportional-hazards model.

Results: Of 1,658 patients with LACC primarily treated with CCRT, 424 (25.6%) had recurrence, with 142, 125, and 157 patients having locoregional, distant, and combined recurrence, respectively. Approximately 75% of recurrence cases were detected within 2 years after completed treatment, and 81.8% of cases demonstrated symptoms at recurrence diagnosis. The median PRS was 8.4 months, and the 1- and 5-year PRS rates were 36.0% and 5.3%, respectively. Multivariate analysis found that the recurrence-free interval (RFI) (p < 0.001), recurrence pattern (p < 0.001), white blood cell count (p < 0.001), and treatment at recurrence (p < 0.001) were independent prognostic factors for PRS.

Conclusion: The prognosis of recurrent LACC initially treated with CCRT was notably poor. RFI, recurrence pattern, white blood cell count, and treatment at recurrence were independent prognostic factors for PRS.

Key words: cervical cancer; recurrence; prognosis; concurrent chemoradiation

Introduction

Currently, patients with locally advanced cervical cancer (LACC) have satisfactory treatment outcomes with concurrent chemoradiation (CCRT), which is a standard treatment for this patient group. A meta-analysis found a 6% improvement in 5-year overall survival with CCRT compared with radiation alone [1]. However, 21.1–30.1% of patients with LACC treated with CCRT experience recurrence [2–4], with 71.5–91.7% of recurrence cases being detected within 2 years [2, 3, 5]. Recurrence could be locoregional, distant, or combined; distant recurrence was found to be predominant after CCRT in a study by Kobayashi et al. [2], whereas Kozaki et al. [4] reported that locoregional recurrence was the primary pattern after CCRT. Treatment modalities after recurrence are limited
and depend on the previous initial treatment, pattern of recurrence, extension of recurrence, and patient performance status (PS) [5–7]. Previous studies found that patients with recurrence had a poor prognosis, with a median post-recurrence survival (PRS) of 16.4–18 months [2, 4].

Identifying the clinicopathologic factors that affect survival after recurrence is important because these factors can be used to predict patient prognosis after recurrence and to counsel the patients. Currently, there is limited information on prognostic factors for PRS in patients with LACC that primarily received CCRT. Moreover, only a few studies, which included a small number of recurrence cases initially treated with CCRT or radiotherapy alone, have reported about these prognostic factors [3–5]. Furthermore, some important prognostic factors that could be associated with PRS were not included in the aforementioned studies [3–5].

Therefore, we conducted this study to evaluate the prognostic factors for PRS in patients with recurrent LACC initially treated with CCRT at a tertiary hospital in Southern Thailand.

Materials and methods

This study was conducted with the approval of the Human Ethics Committee of our institution (IRB number REC.62-303-7-4). We initially included 1,810 patients with cervical cancer stage IB2–IVA (according to International Federation of Gynecology and Obstetrics 2009), who were treated with primary CCRT and completed the planned radiotherapy between December 2002 and December 2018. Patients with incomplete response after primary CCRT (n = 118), histologic subtype other than squamous cell carcinoma, adenocarcinoma (AC), and adenosquamous carcinoma (ASC) (n = 34), were excluded. Of the remaining 1,658 patients, 424 (25.6%) developed recurrence, and we retrospectively reviewed their medical records and data in the Songklanagarind cancer registry.

The patient, disease, and treatment characteristics at initial diagnosis and first recurrence were collected for all eligible patients. The initial diagnosis data consisted of histology and staging. The data at first recurrence included recurrence pattern (locoregional, distant, combined), age at recurrence diagnosis, Eastern Cooperative Oncology Group (ECOG) PS, recurrence-free interval (RFI), symptoms at recurrence, method of recurrence detection, hemoglobin level, white blood cell (WBC) count, platelet count, and treatment modalities after recurrence.

All eligible patients were primarily treated with definitive CCRT. Radiotherapy consisted of external beam radiotherapy (EBRT) and high-dose-rate intracavitary brachytherapy (HDR-ICBT). EBRT was delivered to the whole pelvis or whole pelvis and paraaortic area, in case of paraaortic lymph node involvement. The typical arrangement for the whole-pelvis radiotherapy included opposed anterior-posterior fields or four-field box depending on the physician's decision. The total EBRT dose to whole pelvis was 45–50 Gy in 1.8–2 Gy daily fractions, delivered 5 days per week. Thereafter, a parametrium boost to 54–60 Gy was applied in some patients with parametrium and/or pelvic wall involvement, or at physician's discretion. HDR-ICBT was delivered at 6.5–7 Gy to point A in 4 fractions, once a week. The total dose to point A in most patients was 80–85 Gy in small-volume tumors (≤ 4 cm) and 85–90 Gy in large-volume tumors. Weekly chemotherapy (cisplatin alone) was delivered concurrently with radiotherapy in all eligible patients.

Follow-up was performed 1 month after completion of the primary CCRT and then every 3 months in the first year, every 4 months in the second year, every 6 months in the third to fifth year, and annually thereafter. History taking and physical, pelvic, and rectal examinations were performed in all eligible patients at every follow-up visit. Cervicovaginal cytology, complete blood count, biochemistry profile, and chest radiography were performed annually. Annual computed tomography (CT) of the pelvis, abdomen, and/or chest, or magnetic resonance imaging (MRI) of the pelvis was not routinely performed unless clinically indicated. Positron emission tomography-CT scan is unavailable in our institution and was not used in all eligible patients. A diagnosis of recurrence was based on patient history, physical and pelvic examination, imaging of suspicious lesion, and/or pathological confirmation. Treatment of recurrent disease depended on previous initial treatment, site and extension of recurrence, and patient PS. In this study, treatment at recurrence comprised surgery, chemotherapy, radiotherapy, CCRT, and palliative care, with chemotherapy being the main
treatment. Palliative care was defined as treatment for symptom relief and/or best supportive care. RFI was defined as the time from the completion of primary CCRT to recurrence. PRS was calculated as the time from recurrence diagnosis to death or the last known follow-up.

Comparisons of clinicopathological characteristics between patterns of recurrence were performed using the Chi-square test and Fisher’s exact test for categorical variables. Descriptive statistics were used for patient characteristics and are presented as frequencies and percentages. Survival rates were calculated using the Kaplan-Meier method, and the survival curves of each clinicopathologic factors were compared using the log-rank test. Multivariate analysis of independent factors for PRS was performed using the Cox proportional-hazards model. Statistical significance was set as p < 0.05. All analyses were performed using R version 3.6.1.

**Results**

**Patients and pattern of recurrence**

Of the 1,658 patients with LACC, who were initially treated with primary CCRT, completed the planned radiotherapy, and did not meet the exclusion criteria, 424 (25.6%) developed recurrence and were included in this study.

The clinicopathologic characteristics at initial diagnosis according to recurrence pattern are shown in Table 1; 142 (33.5%), 125 (29.5%), and 157 (37.0%) patients had locoregional, distant, and combined recurrence, respectively. The histologic subtypes were significantly different between the three recurrence patterns (p < 0.001). Locoregional recurrence was significantly the most common recurrence pattern in patients with AC histology. However, the stage at initial diagnosis did not significantly differ between the three recurrence patterns.

The median age at recurrence diagnosis was 51.7 years. More than 80% of the patients had symptoms at the time of recurrence. Asymptomatic recurrence was mainly detected via physical/pelvic examination (34/77 patients, 44.2%). The median RFI was 12.9 [interquartile range (IQR), 7.9–25.4] months; 73.8%, 85.4%, and 96.9% of the patients were diagnosed with recurrence within 2, 3, and 5 years, respectively. The recurrence rate of anemia, leukocytosis, and thrombocytosis were 42.7%, 27.5%, and 34.5%, respectively. The major treatment modality at recurrence was chemotherapy (53.9%), followed by palliative care (33.1%) (Tab. 2).

**Survival analysis**

The median follow-up time after the first recurrence was 6.8 [interquartile range (IQR): 2.8–13.6] months. The median PRS was 8.4 (IQR, 7.3–9.2) months. The 1- and 5-year PRS rates were 36.0% [95% confidence interval (CI): 31.4–41.2] and 5.3% (95% CI: 3.0–9.2), respectively. Univariate analysis found that ECOG performance status (PS) at recurrence (p ≤ 0.001), RFI (p ≤ 0.001), pattern of recurrence (p ≤ 0.001), symptom status (p ≤ 0.001), hemoglobin level (p ≤ 0.001), WBC count (p ≤ 0.001), platelet count (p ≤ 0.001), and treatment at recurrence (p ≤ 0.001) were significant prognostic factors for PRS (Tab. 3). Other factors, including histology, stage, and age, were also included in the univariate analysis but were not significant (Tab. 3).

In the multivariate analysis, RFI [hazard ratio (HR) = 0.7; 95% CI: 0.5–0.8 for RFI > 1

Table 1. Clinicopathologic characteristics at initial diagnosis after definitive concurrent chemoradiation with respect to recurrence pattern in patients with recurrent cervical cancer (n = 424)

| Variable/At initial diagnosis | All patients (n = 424) | Locoregional recurrence (n = 142) | Distant recurrence (n = 125) | Combined recurrence (n = 157) | p-value |
|-----------------------------|-----------------------|----------------------------------|-----------------------------|-----------------------------|---------|
| **Histology**               |                       |                                  |                             |                             |         |
| Squamous cell carcinoma     | 298 (70.3)            | 81 (57.1)                        | 100 (80.0)                  | 117 (74.5)                  | < 0.001 |
| Adenocarcinoma              | 106 (25.0)            | 52 (36.6)                        | 20 (16.0)                   | 34 (21.7)                   |         |
| Adenosquamous carcinoma     | 20 (4.7)              | 9 (6.3)                          | 5 (4.0)                     | 6 (3.8)                     |         |
| **Stage at initial diagnosis** |                       |                                  |                             |                             |         |
| IB2–IIIB                    | 222 (52.4)            | 83 (58.5)                        | 64 (51.2)                   | 75 (47.8)                   | 0.173   |
| IIIA–IVA                    | 202 (47.6)            | 59 (41.5)                        | 61 (48.8)                   | 82 (52.2)                   |         |

Values are presented as n (%); *recurrence patterns not having a superscript in common within clinicopathological characteristics differ significantly (p < 0.05)
year; p < 0.001) (Fig. 1A), pattern of recurrence (HR = 1.5; 95% CI: 1.1–2.0 for distant, HR = 1.7, 95% CI: 1.3–2.2 for combined; p < 0.001) (Fig. 1B), WBC count (HR = 2.0; 95% CI: 1.5–2.7 for WBC count > 10,000/μL; p < 0.001) (Fig. 1C), and treatment at recurrence (HR = 8.7, 95% CI: 2.7–28.6 for palliative care; p < 0.001) (Fig. 1D) were independent prognostic factors for a poor PRS (Tab. 4).

| Variable | Total (n = 424) n (%) |
|----------|-----------------------|
| Age [years] |                         |
| < 40      | 49 (11.6)             |
| 40–55     | 218 (51.4)            |
| > 55      | 157 (37.0)            |
| ECOG score |                       |
| 0–1       | 221 (52.2)            |
| 2–4       | 202 (47.8)            |
| Pattern of recurrence |          |
| Locoregional | 142 (33.5)          |
| Distant    | 125 (29.5)            |
| Combined   | 157 (37.0)            |
| Symptoms |                       |
| No         | 77 (18.2)             |
| Yes        | 345 (81.8)            |
| Method of recurrence detection |          |
| Symptom    | 345 (81.7)            |
| Physical/pelvic examination | 34 (8.1)       |
| Cervicovaginal cytology | 8 (1.9)         |
| Chest radiography | 16 (3.8)      |
| CT/MRI     | 19 (4.5)              |
| Recurrence-free interval (years) |        |
| ≤ 2        | 313 (73.8)            |
| > 2        | 111 (26.2)            |
| Hemoglobin level [g/dL] |          |
| ≤ 10       | 181 (42.7)            |
| > 10       | 222 (52.4)            |
| White blood cell count [/μL] |         |
| ≤ 10,000   | 292 (72.5)            |
| > 10,000   | 111 (27.5)            |
| Platelet count [/μL] |             |
| ≤ 400,000  | 264 (65.5)            |
| > 400,000  | 139 (34.5)            |
| Treatment at recurrence |              |
| Surgery    | 4 (1.0)               |
| Chemotherapy | 220 (53.9)          |
| Radiation  | 47 (11.5)             |
| Concurrent chemoradiation | 2 (0.5)        |
| Palliative care | 135 (33.1)       |

ECOG — Eastern Cooperative Oncology Group; CT — computed tomography, MRI — magnetic resonance imaging.

| Variables | 1-year overall survival (%) (95% CI) | p-value |
|-----------|-------------------------------------|---------|
| At initial diagnosis |                                   |         |
| Histology | Squamous cell carcinoma 33.9 (28.6–40.1) | 0.400   |
|           | Adenocarcinoma 38.0 (29.2–49.5) |         |
|           | Adenosquamous carcinoma 54.2 (36.0–81.6) |         |
| Stage     | IB2–IIIB 37.6 (31.3–45.3) | 0.400   |
|           | IIA–IVA 34.1 (27.9–41.6) |         |
| At first recurrence diagnosis |                                 |         |
| Age [years] |                                      |         |
| < 40       | 39.3 (27.1–57.1) | 0.700   |
| 40–55      | 33.1 (27.0–40.6) |         |
| > 55       | 38.6 (31.4–47.4) |         |
| ECOG score |                                      |         |
| ≤ 1        | 54.6 (48.0–62.0) | < 0.001 |
| > 1        | 15.1 (10.6–21.6) |         |
| Recurrence-free interval [years] |                                 |         |
| ≤ 1        | 31.8 (25.6–39.3) | < 0.001 |
| > 1        | 39.6 (33.3–47.1) |         |
| Symptoms |                                      |         |
| No         | 66.1 (55.8–78.2) | < 0.001 |
| Yes        | 28.6 (23.9–34.2) |         |
| Pattern of recurrence |                                |         |
| Locoregional | 49.5 (41.5–59.0) | < 0.001 |
| Distant    | 37.3 (29.2–47.8) |         |
| Combined   | 23.3 (17.3–31.4) |         |
| Hemoglobin level [g/dL] |                                  | < 0.001 |
| ≤ 10       | 26.0 (19.9–33.8) |         |
| > 10       | 44.3 (37.8–51.8) |         |
| White blood cell count [/μL] |                                | < 0.001 |
| ≤ 10,000   | 45.0 (39.3–51.5) |         |
| > 10,000   | 13.0 (7.9–21.5)  |         |
| Platelet count [/μL] |                                | < 0.001 |
| ≤ 400,000  | 44.6 (38.7–51.4) |         |
| > 400,000  | 19.3 (13.3–28.1) |         |
| Treatment at recurrence |                                 | < 0.001 |
| Surgery    | 100 |         |
| Chemotherapy | 46.9 (40.3–54.5) |
| Radiation  | 52.2 (39.6–68.8) |         |
| Concurrent chemoradiation | 100 |         |
| Palliative care | 10.5 (6.2–17.8) |
Discussion

The percentage of LACC recurrence (25.6%) in our study was observed to be consistent with that in previous studies (21.1–30.1%); these studies mainly included cases of LACC initially treated with CCRT [2–4]. Combined recurrence was the most common pattern of recurrence in the current study (37%). These results suggest that recurrence of primary LACC was mostly discovered at an advanced stage of disease. Our results are not consistent with those from earlier studies with heterogeneity of stage, initial workup modalities, initial treatment with CCRT or radiotherapy alone which found that distant recurrence was the most common recurrence pattern [2, 8]. In addition, one study that included a small number of patients with persistent disease found that local recurrence was the major recurrence pattern [4]. The present study found that locoregional recurrence was significantly more frequent than other recurrence patterns in patients with AC histology. Our result is in accordance with that of Yokoi et al. [9]; in their study, 94.4% of LACC patients received CCRT, and the AC/ASC
group (1/16 patients had ASC) had a higher proportion of locoregional recurrence (20%) than distant (11.9%) and combined recurrence (0%), but a p-value was not calculated. These results may be explained by the radioresistant nature of AC histology [10–14]; thus, patients with AC have a high possibility of microscopic disease in the pelvis even after treatment [15]. Our study proposes that patients with AC should receive more intensive local treatment.

Regarding symptoms at recurrence, the majority of those with recurrence (81.4%) in the current study had symptoms at the diagnosis of recurrence, which is in line with a previous study of early-stage cervical cancer from the same institute, which found more cases of symptomatic (63.1%) than asymptomatic (33.3%) recurrence [16]. In the current study, physical/pelvic examination was able to detect a high percentage of cases of asymptomatic recurrence (44.2%). Similarly, a systematic review by Elit et al. [17] found that complete physical examination detected the largest number of recurrence cases (29–71%). Hence, physical/pelvic examination is one of the important methods for recurrence detection and should be thoroughly performed at every follow-up visit.

Radiologic imaging in our study, including chest radiography and CT/MRI, had a moderate rate of recurrence detection (20.8% and 24.7%, respectively), which is also concordant with the aforementioned systematic review [17]. However, a Japanese study [5] reported a high rate of detection of asymptomatic recurrence (65%) via radiologic imaging, which is higher than noted in our report and in the systematic review by Elit et al. [17]. This may be because the surveillance protocol in the Japanese study included an intensive follow-up program that involved frequent radiologic imaging. One probable reason our study found a high proportion of symptomatic recurrence was because follow-up imaging studies were not routinely performed based on our follow-up protocol, which caused some asymptomatic cases of recurrence to be missed. Thus, routine radiologic imaging during the follow-up period seems essential and requires further investigation.

Considering cervicovaginal cytology, our result showed the lowest rate of recurrence detection in

### Table 4. Multivariate analysis of prognostic factors for overall post-recurrence survival

| Variable                        | HR  | 95% CI        | p-value |
|---------------------------------|-----|---------------|---------|
| **Recurrence-free interval [years]** |     |               |         |
| ≤ 1                             | 1   | –             | < 0.001 |
| > 1                             | 0.7 | 0.5–0.8       |         |
| **Pattern of recurrence**       |     |               |         |
| Locoregional                    | 1   | –             | < 0.001 |
| Distant                         | 1.5 | 1.1–2.0       | 0.004   |
| Combined                        | 1.7 | 1.3–2.2       | < 0.001 |
| **Hemoglobin level [g/dL]**     |     |               |         |
| ≤ 10                            | 1   | –             | 0.184   |
| > 10                            | 0.8 | 0.7–1.1       |         |
| **White blood cell count [μL]** |     |               | < 0.001 |
| ≤ 10,000                        | 1   | –             |         |
| > 10,000                        | 2.0 | 1.5–2.7       |         |
| **Platelet count [μL]**         |     |               | 0.970   |
| ≤ 400,000                       | 1   | –             |         |
| > 400,000                       | 1.0 | 0.8–1.3       |         |
| **Treatment at recurrence**     |     |               | < 0.001 |
| Surgery                         | 1   | –             |         |
| Chemotherapy                    | 2.7 | 0.8–8.7       | 0.099   |
| Radiation                       | 3.0 | 0.9–10.1      | 0.072   |
| Concurrent chemoradiation       | 3.2 | 0.3–32.7      | 0.318   |
| Palliative care                 | 8.7 | 2.7–28.6      | < 0.001 |

HR — hazard ratio; CI — confidence interval

https://journals.viamedica.pl/rpor
asymptomatic patients with this method (10.4%), which is in accordance with a previous systematic review that showed that 0–17% of patients with recurrence were detected with cervicovaginal cytology [17]. However, currently, the role of HPV-DNA testing as a follow-up tool is arousing interest. A recent systematic review and meta-analysis in India that included 10 cohort studies reported high sensitivity (0.84, 95% CI: 0.66–0.94) but low specificity (0.35, 95% CI: 0.20–0.54) of HPV-DNA testing for recurrence detection after pelvic irradiation [18]. Thus, the current practice guidelines do not recommend HPV-DNA testing for surveillance [19–21].

In the present study, the patients had a relatively short RFI, with approximately 75% of the patients experiencing recurrence within 2 years. Our study is in accordance with previous research on locally advanced stage [2, 3, 5]. Nonetheless, we found that the proportion of patients with RFI within 2 years in our study was larger than noted in a study of early-stage disease at the same institute, which reported that less than half of patients were detected with recurrence within 2 years [16]. Since locally advanced stage tumors have more aggressive clinical behavior than early-stage tumors.

The median PRS (8.4 months) of patients in our study was notably poor and was shorter than that noted in two preceding-CCRT era studies (16.4–18 months) [2,4]. These differences may be because 15% of the patients in the study by Kabayashi et al. [2] were stage IB1, while there was no patient with stage IB1 in our study. Moreover, the Kozaki et al. study [4] included only patients that received chemotherapy as the treatment at recurrence which indicated that their study had a higher percentages of patients with good PS than our study. Our study also had a high percentage of patients with ECOG PS 2–4 at recurrence (47.8%), who probably could not receive intensive treatment, resulting in the poor PRS. Concerning the prognostic factors for PRS, previous studies that mainly included LACC patients who were initially treated with CCRT or radiotherapy alone found that RFI [4], site of recurrence [3,5] and treatment modalities at recurrence [5] were independent prognostic factors for PRS as noted in our study. Moreover, it is interesting that the current study found that leukocytosis (WBC count > 10,000/μL) was a novel independent prognostic factor, which has been uniden-
Acknowledgments
We would like to thank the Epidemiology Unit of Prince of Songkla University for providing assistance in the data analysis.

References

1. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010(1): CD008285, doi: 10.1002/14651858. CD008285, indexed in Pubmed: 20091664.

2. Kobayashi R, Yamashita H, Okuma K, et al. Details of recurrence sites after definitive radiation therapy for cervical cancer. J Gynecol Oncol. 2016; 27(2): e16, doi: 10.3802/jgo.2016.27.2.e16, indexed in Pubmed: 26463432.

3. Seebacher V, Sturzda A, Bergmeister B, et al. Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score. Arch Gynecol Obstet. 2019; 299(4): 1055–1062, doi: 10.1007/s00404-018-4993-0, indexed in Pubmed: 30535923.

4. Kozaki M, Sakuma S, Kudaka W, et al. Management of recurrent squamous cell carcinoma. J Gynecol Oncol. 2010; 21(5): 834–840, doi: 10.1111/j.1607-4126.2010.01312.x, indexed in Pubmed: 20606531.

5. Peiretti M, Zampaderi I, Zanagnolo V, et al. The impact of histological subtype on survival in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy. Arch Gynecol Obstet. 2017; 296(5): 997–1003, doi: 10.1007/s00404-017-4520-8, indexed in Pubmed: 28884382.

6. Mabuchi S, Ishoishi F, Yoshioka Y, et al. Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer. 2010; 20(5): 834–840, doi: 10.1111/j.1607-4126.2010.01312.x, indexed in Pubmed: 20606531.

7. Peiretti M, Zampaderi I, Zanagnolo V, et al. Management of recurrent cervical cancer: a review of the literature. Surg Oncol. 2012; 21(2): e59–e66, doi: 10.1016/j.suronc.2011.12.008, indexed in Pubmed: 22244884.

8. Gadducci A, Tana R, Cosio S, et al. Treatment options in recurrent cervical cancer (Review). Oncol Lett. 2010; 1(1): 3–11, doi: 10.3892/ol_00000001, indexed in Pubmed: 22966247.

9. Hong JH, Tsai CS, Lai CH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 60(1): 249–257, doi: 10.1016/j.ijrobp.2004.02.044, indexed in Pubmed: 15337563.

10. Yoko I, Mabuchi S, Takahashi R, et al. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. J Gynecol Oncol. 2017; 28(2): e19, doi: 10.3802/jgo.2017.28.e19, indexed in Pubmed: 28028992.

11. Chen JLY, Huang CY, Huang YS, et al. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstet Gynecol Scand. 2014; 93(7): 661–668, doi: 10.1111/aogs.12383, indexed in Pubmed: 24666257.
22(9): 1545–1551, doi: 10.1097/IGC.0b013e31826ea0eb, indexed in Pubmed: 23051956.

23. Matsumoto Y, Mabuchi S, Muraji M, et al. Squamous cell carcinoma of the uterine cervix producing granulocyte colony-stimulating factor: a report of 4 cases and a review of the literature. Int J Gynecol Cancer. 2010; 20(3): 417–421, doi: 10.1111/IGC.0b013e3181d15a11, indexed in Pubmed: 20375807.